Torrent Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.86×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.13×	1.13×	1.19×	1.03×	0.98×
0.75×	0.75×	0.65×	0.61×	0.57×
2,964	1,983	685	976	664
2,533	1,049	906	185	−133

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TORNTPHARM₹4,580.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA JBCHEPHARM MANKIND ZYDUSLIFE DIVISLAB MAXHEALTH DRREDDY CIPLAMcap ₹1.55L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.86
Current Ratio	0.98	1.03	1.19	1.13	1.13
Quick Ratio	0.57	0.61	0.65	0.75	0.75
Cash, Equiv & ST Investments	664.0	976.0	685.0	1,983.0	2,964.0
Working Capital	-133.0	185.0	906.0	1,049.0	2,533.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.